Car-T Cell Therapy Targets

802 products

CAR-T cell therapy is an innovative immune cell therapy used to treat certain types of cancer. It uses a recombinant chimeric antigen receptor (CAR) to genetically engineer a patient's T cells to recognize and attack cancer cells. The key to CAR-T cell therapy is to introduce CAR into the patient's T cells through genetic engineering technology. CAR is a synthetic protein consisting of an external monoclonal antibody binding domain and an internal T cell activation signaling molecule. The outer binding domain can bind to specific cancer cell surface antigens, and the inner activation signal can activate T cells and trigger an immune response.

Chimeric Antigen Receptor Between T-Cell and Cancer Cell

The process of CAR-T cell therapy involves three main steps: obtaining T cells, genetic modification and reinfusion. First, T cells are extracted from the patient's blood, and these cells are cultured and proliferated in vitro to form a large number of T cells. Secondly, the CAR gene is introduced into T cells by using genetic engineering techniques such as viral vectors or transposases, so that they can express the CAR protein. In this way, CAR-T cells have the ability to specifically recognize and attack specific cancer cells. Finally, after strict quality control and expansion, the engineered CAR-T cells were reinfused into the patient.

Once CAR-T cells are inside a patient, they seek out and bind to antigens on the surface of target cancer cells. This binding triggers a signaling pathway inside the CAR that activates T cells and releases cytotoxic substances, such as perforin and cytotoxic factors, to directly kill cancer cells. In addition, CAR-T cells can also activate other immune cells, such as natural killer cells and macrophages, enhancing the overall anti-cancer immune response.

CAR-T cell therapy has been shown to achieve remarkable efficacy in the treatment of certain hematological tumors, such as acute lymphoblastic leukemia and non-Hodgkin's lymphoma. With the development of technology and the deepening of research, CAR-T cell therapy is also expanding to other types of cancer treatment. It provides cancer patients with an individualized, highly effective and promising treatment option. 

Beta LifeScience offers a variety of target proteins for hematological and solid tumors, which include, but are not limited to, breast, pancreatic, and lung cancer. These proteins are available in various tags, catering to diverse research and development needs, such as CAR expression analysis. We have developed expression systems that ensure accurate protein folding and post-translational modifications, thus providing a valuable tool for your drug discovery endeavors.


    802 products